MedPage Today

@medpagetoday.com

Better informed, better care. #MedPageToday Reposts, likes, and comments are not endorsements.

Bone growth among transgender and gender-diverse adolescents slowed compared with peers during pubertal suppression, but partially recovered after starting gender-affirming hormone therapy, an analysis showed. Read more at: https://www.medpagetoday.com/endocrinology/transgender-medicine/122471

Bone Density Appears to Rebound in Transgender Youth After Puberty Blockers Are Done

Meta-analysis turns up partial recovery after gender-affirming hormone therapy is started

medpagetoday.com

Only one person has developed a new HIV infection during a year-long extension of the landmark PURPOSE 1 and PURPOSE 2 trials testing twice-yearly injectable lenacapavir (Yeztugo) for pre-exposure prophylaxis (PrEP). Read more at: https://www.medpagetoday.com/meetingcoverage/iac/122449

Long-Acting Lenacapavir Still Delivered Effective HIV PrEP After a Year

Only one person developed HIV infection in year-long extensions of two PURPOSE trials

medpagetoday.com

Periurethral application of a smaller amount of estradiol cream with a finger was noninferior to standard intravaginal application with an applicator among postmenopausal patients with recurrent UTIs, the TAPER randomized trial found. https://www.medpagetoday.com/obgyn/generalobgyn/122406

Study on Vaginal Estrogen for UTI Prevention Backs a Less Messy Approach

Periurethral and intravaginal creams both aided prevention of recurrent urinary tract infections

medpagetoday.com

"Don't dismiss it -- recognize an algorithm may have figured out their unique concerns and fed them the exact piece of information, doubt, or worry that will keep them up at night." Read the #OpEd from Kristen Panthagani, MD, PhD, at: https://www.medpagetoday.com/opinion/second-opinions/122391

Opinion | What Falling Into the Social Media Vortex Taught Me About My Patients

People aren't 'looking' for health information on social platforms, it finds them

medpagetoday.com

Switching to a weekly oral investigational regimen of islatravir and lenacapavir was just as effective as daily oral standard-of-care regimens in patients with virologically suppressed HIV, according to two phase III trials. #AIDS2026 https://www.medpagetoday.com/meetingcoverage/iac/122416

Once-Weekly Drug Combo for Controlled HIV Matches Standard Daily Regimens

Weekly regimen has the potential to address pill fatigue, adherence challenges, researcher says

medpagetoday.com